Poly(ADP-ribose) Polymerase Inhibitor Talazoparib Inhibits DNA Damage Repair in Breast Cancer Cell Lines With or Without BRCA1/2 Mutation
Authors:
Open Access
- 1 January 2026
- journal article
- Published by XMLink in Journal of Breast Cancer
- Vol. 29 (5) , 395
Abstract
Lee M, et al. J Breast Cancer. 2026 ;29:e34. https://doi.org/10.4048/jbc.2026.0085Keywords
Funding Information
- National Research Foundation of Korea (RS-2024-00454656)
This publication has 25 references indexed in Scilit:
- Hallmarks of DNA replication stressMolecular Cell, 2022
- An Overview of PARP Inhibitors for the Treatment of Breast CancerTargeted Oncology, 2021
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Profiling DNA damage response following mitotic perturbationsNature Communications, 2016
- PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directionsBritish Journal of Cancer, 2016
- Replication stress activates DNA repair synthesis in mitosisNature, 2015
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- The DNA damage response and cancer therapyNature, 2012
- The DNA-damage response in human biology and diseaseNature, 2009
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005